Mechanistically, HRD-EXCUTE prompts higher tumor mutation burden and more neoantigens to inflame tumor microenvironment, significantly boosting B cells, CD4+ T cells, CD8+ T cells, etc. Moreover, we found that the HDAC deacetylation was significantly activated in HRD patients without HRD-EXCUTE. Here, HDAC9 is linked to neoplasm.